Healwell AI (AIDX) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 2024 revenue of CAD 15.2 million (up 692% year-over-year) and full-year revenue of CAD 38.9 million, driven by acquisitions and AI commercialization.

• Announced acquisition of Orion Health, expected to close in April 2025, anticipated to add over CAD 100 million in annual revenue and drive EBITDA profitability.

• Completed four strategic acquisitions in 2024, including Intrahealth Solutions, VeroSource Solutions, Bio Pharma Services, and Mutuo Health Solutions.

• Positioned as a leading, fast-growing healthcare AI provider, focusing on preventative care, early disease detection, and expanding global reach.

Financial highlights

• 2024 revenue was approximately CAD 39 million, up from CAD 7.3 million in 2023; gross profit reached CAD 17 million, with gross margin rising to 44%.

• Q4 2024 gross profit was CAD 7 million, up 1,179% year-over-year, with a gross margin of 46%.

• Adjusted EBITDA loss for 2024 was CAD 16 million; Q4 2024 adjusted EBITDA loss was CAD 5.5 million.

• Net loss for 2024 was CAD 26.6 million, compared to CAD 32.1 million in 2023.

• Ended 2024 with CAD 9.4 million in cash; subsequent financings and credit agreements provide additional liquidity.

Outlook and guidance

• Orion Health acquisition expected to close in April 2025, adding over CAD 100 million in annual revenue and driving EBITDA profitability.

• 2025 goals include integrating Orion Health, executing further M&A, accelerating organic growth, and leveraging the Buy Canadian opportunity.

• AI and data science revenue expected to double in 2025; healthcare software segment to approach CAD 100 million with Orion; clinical research revenue expected to grow 50%.

• Gross margin for 2025 projected around 50% on a combined entity basis.

• Cost optimization initiatives expected to yield at least CAD 3 million in annual savings.